Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf > MEK > ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK

Radiotherapy and Oncology

Volumn 93, Issue 3, 2009, Pages 639-644

  Sambade, Maria J ^a,c   Camp, J Terese ^a,c   Kimple, Randall J ^a,c   Sartor, Carolyn I ^a,c   Shields, Janiel M ^a,b,c  

^a Department of Radiation Oncology ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; CI 1040; EGFR; Lapatinib; MEK ERK; Resistance

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B BETA; RAF PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; WESTERN BLOTTING;

ANTHRACENES; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEINS C-RAF; QUINAZOLINES; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 70449686563     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.09.006     Document Type: Article

References (52)

1. Kvols L.K. Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. J Nucl Med 46 (2005) 187S-190S
2. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
3. Fadare O., and Tavassoli F.A. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 14 (2007) 358-373
4. Fadare O., and Tavassoli F.A. Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol 5 (2008) 149-159
5. Finnegan T.J., and Carey L.A. Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 3 (2007) 55-63
6. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
7. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
8. Zhou H., Kim Y.S., Peletier A., McCall W., Earp H.S., and Sartor C.I. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58 (2004) 344-352
9. Hoadley K.A., Weigman V.J., Fan C., et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8 (2007) 258
10. Temam S., Kawaguchi H., El-Naggar A.K., et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25 (2007) 2164-2170
11. Gee J.M., and Nicholson R.I. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res 5 (2003) 126-129
12. Hynes N.E., and MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21 (2009) 177-184
13. Gusterson B.A., and Hunter K.D. Should we be surprised at the paucity of response to EGFR inhibitors?. Lancet Oncol 10 (2009) 522-527
14. Rakha E.A., Reis-Filho J.S., and Ellis I.O. Basal-like breast cancer: a critical review. J Clin Oncol 26 (2008) 2568-2581
15. Grana T.M., Rusyn E.V., Zhou H., Sartor C.I., and Cox A.D. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62 (2002) 4142-4150
16. Sartor C.I., Zhou H., Kozlowska E., et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21 (2001) 4265-4275
17. Ho C., and Laskin J. EGFR-directed therapies to treat non-small-cell lung cancer. Expert Opin Investig Drugs 18 (2009) 1133-1145
18. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83 (2007) 238-248
19. Milano G., and Magne N. Anti-EGFR and radiotherapy. Cancer Radiother 8 (2004) 380-382
20. Sartor C.I. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 1 (2004) 80-87
21. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
22. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 701-708
23. Buchsbaum D.J., Bonner J.A., Grizzle W.E., et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 54 (2002) 1180-1193
24. Huang S.M., Li J., Armstrong E.A., and Harari P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (2002) 4300-4306
25. Shintani S., Li C., Mihara M., et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107 (2003) 1030-1037
26. Nyati M.K., Maheshwari D., Hanasoge S., et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10 (2004) 691-700
27. Magne N., Chargari C., Castadot P., et al. The efficacy and toxicity of EGFR in the settings of radiotherapy: focus on published clinical trials. Eur J Cancer 44 (2008) 2133-2143
28. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61 (2001) 3986-3997
29. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8 (2002) 885-892
30. Toulany M., Baumann M., and Rodemann H.P. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 5 (2007) 863-872
31. Toulany M., Dittmann K., Kruger M., Baumann M., and Rodemann H.P. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol 76 (2005) 143-150
32. Grana T.M., Sartor C.I., and Cox A.D. Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res 63 (2003) 7807-7814
33. Dent P., Reardon D.B., Park J.S., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10 (1999) 2493-2506
34. Pirollo K.F., Tong Y.A., Villegas Z., Chen Y., and Chang E.H. Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat Res 135 (1993) 234-243
35. Mirzoeva O.K., Das D., Heiser L.M., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69 (2009) 565-572
36. Dent P., Yacoub A., Contessa J., et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159 (2003) 283-300
37. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., and Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 59 (1999) 2457-2463
38. Verheij M., Bose R., Lin X.H., et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380 (1996) 75-79
39. Bain J., Plater L., Elliott M., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 408 (2007) 297-315
40. Garcia R., Bowman T.L., Niu G., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 (2001) 2499-2513
41. Ma J., Ye L., Da M., and Wang X. Heavy ion irradiation increases apoptosis and STAT-3 expression, led to the cells arrested at G2/M phase in human hepatoma SMMC-7721 cells. Mol Cell Biochem 328 (2009) 17-23
42. Skvortsova I., Skvortsov S., Stasyk T., et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8 (2008) 4521-4533
43. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
44. Nahta R., and Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8 (2006) 215
45. Ryan Q., Ibrahim A., Cohen M.H., et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13 (2008) 1114-1119
46. Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297 (2002) 63-64
47. Pillay V., Allaf L., Wilding A.L., et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11 (2009) 448-458 442 p following 458
48. Wheeler D.L., Huang S., Kruser T.J., et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27 (2008) 3944-3956
49. Janmaat M.L., Kruyt F.A., Rodriguez J.A., and Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9 (2003) 2316-2326
50. Nahta R., Yuan L.X., Du Y., and Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6 (2007) 667-674
51. Shaul Y.D., and Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773 (2007) 1213-1226
52. Luo J., Solimini N.L., and Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136 (2009) 823-837